Get all your news in one place.
100's of premium titles.
One app.
Start reading
Reuters
Reuters
Business
Michael Erman

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Empty vials of Pfizer-BioNTech COVID-19 vaccine for children over 5 are pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., May 19, 2022. REUTERS/Hannah Beier/File Photo

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

The companies said they plan to soon ask global regulators to authorize the shot for the age group, children for whom no vaccine is currently approved in most of the world. They said they expect to complete their submission of data to the U.S. Food and Drug Administration (FDA) this week.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.